Mountain View, CA

Northern California Retina Vitreous Associates Medical Group

Wet Macular Degeneration

Macular Degeneration

Diabetic Retinopathy

Retinal Diseases

AR-14034

AbbVie

Aerie Pharmaceuticals

condition

allSponsorName

Alcon

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in subjects with neovascular age-related macular degeneration (nAMD).

Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Northern California Retina Vitreous Associates Medical Group | Mountain View, CA

Site insights

Work at this site?

Active trials

Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD) (NOVA-1)

Trial sponsors